NZ577716A - Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1h-pyrazol-3-yl) phenoxy)methyl)quinoline - Google Patents

Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1h-pyrazol-3-yl) phenoxy)methyl)quinoline

Info

Publication number
NZ577716A
NZ577716A NZ577716A NZ57771607A NZ577716A NZ 577716 A NZ577716 A NZ 577716A NZ 577716 A NZ577716 A NZ 577716A NZ 57771607 A NZ57771607 A NZ 57771607A NZ 577716 A NZ577716 A NZ 577716A
Authority
NZ
New Zealand
Prior art keywords
methyl
disorders
succinate salt
pyrazol
pyridin
Prior art date
Application number
NZ577716A
Other languages
English (en)
Inventor
Patrick Robert Vorhoest
Caroline Proulx
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39321475&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ577716(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NZ577716A publication Critical patent/NZ577716A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ577716A 2006-12-21 2007-12-03 Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1h-pyrazol-3-yl) phenoxy)methyl)quinoline NZ577716A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87126006P 2006-12-21 2006-12-21
PCT/IB2007/003819 WO2008084299A1 (en) 2006-12-21 2007-12-03 Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1h-pyrazol-3-yl) phenoxy)methyl)quinoline

Publications (1)

Publication Number Publication Date
NZ577716A true NZ577716A (en) 2012-10-26

Family

ID=39321475

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ577716A NZ577716A (en) 2006-12-21 2007-12-03 Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1h-pyrazol-3-yl) phenoxy)methyl)quinoline

Country Status (24)

Country Link
US (1) US8283471B2 (enExample)
EP (1) EP2125786B1 (enExample)
JP (1) JP5254602B2 (enExample)
KR (2) KR20090092338A (enExample)
CN (1) CN101611029B (enExample)
AR (1) AR064417A1 (enExample)
AT (1) ATE502028T1 (enExample)
AU (1) AU2007343135B2 (enExample)
BR (1) BRPI0720936A2 (enExample)
CA (1) CA2673435C (enExample)
CY (1) CY1111919T1 (enExample)
DE (1) DE602007013294D1 (enExample)
DK (1) DK2125786T3 (enExample)
ES (1) ES2360014T3 (enExample)
IL (1) IL199389A (enExample)
MX (1) MX2009006528A (enExample)
NZ (1) NZ577716A (enExample)
PL (1) PL2125786T3 (enExample)
PT (1) PT2125786E (enExample)
RU (1) RU2430918C2 (enExample)
SI (1) SI2125786T1 (enExample)
TW (1) TWI359660B (enExample)
WO (1) WO2008084299A1 (enExample)
ZA (1) ZA200904230B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010033045A1 (en) * 2008-09-16 2010-03-25 Igor Anatolievich Pomytkin Compositions and methods for prevention or treatment of beta amyloid deposition
TWI396689B (zh) 2008-11-14 2013-05-21 Amgen Inc 作為磷酸二酯酶１０抑制劑之吡衍生物
US20120214842A1 (en) * 2011-02-18 2012-08-23 Exonhit Therapeutics Sa Methods for treating diseases of the retina
EP2975037A4 (en) 2013-03-15 2016-08-10 Daiichi Sankyo Co Ltd benzothiophene derivative
US10039764B2 (en) 2013-07-12 2018-08-07 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression
KR102233916B1 (ko) * 2019-05-28 2021-03-30 주식회사 엘지생활건강 Pq1 숙신산을 포함하는 피부 보습, 주름 개선 및 탄력 증진용 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4105551A1 (de) * 1991-02-22 1992-08-27 Bayer Ag 2-substituierte chinoline, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
EA011451B1 (ru) * 2001-02-12 2009-04-28 Уайт Новая соль сукцинат о-десметилвенлафаксина
IL161326A0 (en) * 2001-11-29 2004-09-27 Pfizer Prod Inc Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2 (11),3,5,7,9-pentaene and pharmaceutical compositions thereof
CN1608062A (zh) * 2001-12-12 2005-04-20 辉瑞产品公司 E－2－甲氧基－n－(3－{4－[3－甲基－4－(6－甲基－吡啶－3－基氧基) －苯氨基]－喹唑啉－6基}－烯丙基)－乙酰胺的盐，其制备和抗癌用途
CA2536073A1 (en) * 2003-08-18 2005-02-24 H. Lundbeck A/S Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
WO2006072828A2 (en) * 2005-01-07 2006-07-13 Pfizer Products Inc. Heteroaromatic quinoline compounds and their use as pde10 inhibitors
WO2006078825A2 (en) 2005-01-21 2006-07-27 Cabot Corporation Processes for forming nanoparticles
AU2006329849A1 (en) * 2005-12-16 2007-07-05 Wyeth Lyophilized compositions of a triazolopyrimidine compound

Also Published As

Publication number Publication date
CA2673435C (en) 2012-10-09
KR20090092338A (ko) 2009-08-31
BRPI0720936A2 (pt) 2014-03-11
AR064417A1 (es) 2009-04-01
ATE502028T1 (de) 2011-04-15
JP5254602B2 (ja) 2013-08-07
AU2007343135A1 (en) 2008-07-17
IL199389A (en) 2014-01-30
CN101611029A (zh) 2009-12-23
HK1134670A1 (en) 2010-05-07
EP2125786B1 (en) 2011-03-16
PL2125786T3 (pl) 2011-07-29
EP2125786A1 (en) 2009-12-02
SI2125786T1 (sl) 2011-05-31
TWI359660B (en) 2012-03-11
MX2009006528A (es) 2009-06-26
WO2008084299A1 (en) 2008-07-17
PT2125786E (pt) 2011-04-21
US20100063089A1 (en) 2010-03-11
CY1111919T1 (el) 2015-11-04
ES2360014T3 (es) 2011-05-31
RU2009123347A (ru) 2011-01-27
ZA200904230B (en) 2010-04-28
TW200833337A (en) 2008-08-16
AU2007343135B2 (en) 2013-03-21
JP2008208114A (ja) 2008-09-11
RU2430918C2 (ru) 2011-10-10
CA2673435A1 (en) 2008-07-17
DK2125786T3 (da) 2011-05-09
DE602007013294D1 (de) 2011-04-28
KR20120043775A (ko) 2012-05-04
CN101611029B (zh) 2014-09-10
US8283471B2 (en) 2012-10-09

Similar Documents

Publication Publication Date Title
NO20074368L (no) Syklopentapyridin- og tetrahydroquinolinderivater
HRP20110781T1 (hr) Derivati azabiciklo[3.1.0]heksana, korisni kao modulatori dopaminskih receptora d3
NO20090172L (no) Substituert spiroketalderivat og anvendelse derav som legemiddel for a behandle diabetes
TW200716648A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
MX2011011875A (es) Compuesto de carboxamida heterociclica diamino.
TW200738729A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
IL183662A0 (en) Process for the preparation of a 2-pyridylethylcarboxamide derivative
WO2010151710A3 (en) Substituted heterocyclic compounds as kinases inhibitors and method of use thereof
NZ600674A (en) Quinoline amide m1 receptor positive allosteric modulators
MX2011008389A (es) Sal de tipo tosilato de un derivado de 5-pirazolil-2-piridona, util en el tratamiento de la enfermedad pulmonar obstructiva cronica (epoc).
NZ598582A (en) Novel phenol derivative having uricsuric effect
PL2321295T3 (pl) Pochodne 4-(pirydyn-4-ylo)-1H-[1,3,5]triazyn -2-onu jako inhibitory GSK2-beta do leczenia chorób degeneracyjnych
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
TNSN07164A1 (en) Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists
UA92349C2 (ru) Полиморфы этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}-1-метил-1н-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты
NZ590954A (en) Compounds as kinase inhibitors
TW200640900A (en) 1-(2h)-isoquinolone derivative
MX2012000577A (es) Compuestos de amino spiro apropiados para el tratamiento entre otras cosas de trastornos de sueño y adiccion a los farmacos.
MY141780A (en) 5-substituted quinoline and isoquinoline derivatives, a method for the production thereof and their use as antiphlogistics
MY151229A (en) Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound
NO20080033L (no) Kinolinderivater som NK3-antagonister
US20230121578A1 (en) Small molecule modulators of the btb domain of keap1
TW200833337A (en) Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinoline
WO2012077135A3 (en) Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof
TW200726764A (en) N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 03 DEC 2014 BY AJ PARK

Effective date: 20130318

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 03 DEC 2017 BY THOMSON REUTERS

Effective date: 20140912

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 DEC 2018 BY THOMSON REUTERS

Effective date: 20171120

LAPS Patent lapsed